See more : Skyworks Solutions, Inc. (AWM.DE) Income Statement Analysis – Financial Results
Complete financial analysis of Better Therapeutics, Inc. (BTTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Better Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Soulbrain Co., Ltd. (357780.KQ) Income Statement Analysis – Financial Results
- Mon Courtier Energie Groupe S.A. (ALMCE.PA) Income Statement Analysis – Financial Results
- Fujitec Co., Ltd. (FJTCY) Income Statement Analysis – Financial Results
- China Railway Group Limited (0390.HK) Income Statement Analysis – Financial Results
- SC Asset Corporation Public Company Limited (SC-R.BK) Income Statement Analysis – Financial Results
Better Therapeutics, Inc. (BTTX)
About Better Therapeutics, Inc.
Better Therapeutics, Inc. engages in developing software-based prescription digital therapeutics (PDT) platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions in the United States. Its lead product candidate in development is BT-001, an investigational PDT platform that uses digitally delivered Nutritional Cognitive Behavioral Therapy to treat type 2 diabetes. The company's products under development also include BT-002, a PDT that help patients with hypertension improve their blood pressure; and BT-003, a PDT that help patients with hyperlipidemia enhance cholesterol levels. Better Therapeutics, Inc. was founded in 2015 and is headquartered in San Francisco, California.
| Metric | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 8.00K | 18.00K |
| Cost of Revenue | 2.73M | 1.62M | 682.00K | 898.00K |
| Gross Profit | -2.73M | -1.62M | -674.00K | -880.00K |
| Gross Profit Ratio | 0.00% | 0.00% | -8,425.00% | -4,888.89% |
| Research & Development | 16.44M | 19.44M | 2.98M | 2.29M |
| General & Administrative | 14.84M | 8.79M | 2.46M | 2.20M |
| Selling & Marketing | 6.98M | 2.34M | 216.00K | 406.00K |
| SG&A | 21.82M | 11.12M | 2.67M | 2.60M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 38.26M | 30.56M | 5.65M | 4.89M |
| Cost & Expenses | 38.26M | 30.56M | 6.33M | 5.79M |
| Interest Income | 1.49K | 185.00 | 100.00 | 11.00 |
| Interest Expense | 1.49M | 185.00K | 100.00K | 11.00K |
| Depreciation & Amortization | 2.73M | 1.62M | 75.00K | 72.00K |
| EBITDA | -38.26M | -30.56M | -6.25M | -5.70M |
| EBITDA Ratio | 0.00% | 0.00% | -78,100.00% | -31,672.22% |
| Operating Income | -38.26M | -30.56M | -6.32M | -5.77M |
| Operating Income Ratio | 0.00% | 0.00% | -79,037.50% | -32,072.22% |
| Total Other Income/Expenses | -1.49M | -9.93M | 89.00K | -11.00K |
| Income Before Tax | -39.75M | -40.49M | -6.23M | -5.78M |
| Income Before Tax Ratio | 0.00% | 0.00% | -77,925.00% | -32,133.33% |
| Income Tax Expense | 7.00K | -153.00K | 153.00K | 11.00K |
| Net Income | -39.76M | -40.34M | -6.39M | -5.80M |
| Net Income Ratio | 0.00% | 0.00% | -79,837.50% | -32,194.44% |
| EPS | -1.69 | -1.71 | -0.85 | -0.25 |
| EPS Diluted | -1.69 | -1.71 | -0.85 | -0.25 |
| Weighted Avg Shares Out | 23.56M | 23.60M | 7.56M | 23.60M |
| Weighted Avg Shares Out (Dil) | 23.56M | 23.60M | 7.56M | 23.60M |
Better Therapeutics SPAC Merger: 8 Things for BTTX Stock Investors to Know
Source: https://incomestatements.info
Category: Stock Reports